

DRUG METABOLISM AND DISPOSITION

A Publication of the American Society for Pharmacology and Experimental Therapeutics

September 2016

Vol. 44, No. 9

CONTENTS

MINIREVIEW

The Complexities of Interpreting Reversible Elevated Serum Creatinine Levels in Drug Development: Does a Correlation with Inhibition of Renal Transporters Exist?. *Xiaoyan Chu, Kelly Bleasby, Grace Hoyee Chan, Irene Nunes, and Raymond Evers* . . . **1498**

ARTICLES

▣ Arylsulfatase B Mediates the Sulfonation-Transport Interplay in Human Embryonic Kidney 293 Cells Overexpressing Sulfotransferase 1A3. *Mengjing Zhao, Shuai Wang, Feng Li, Dong Dong, and Baojian Wu* **1441**

▣ The Absolute Bioavailability and Effect of Food on the Pharmacokinetics of Odanacatib: A Stable-Label i.v./Oral Study in Healthy Postmenopausal Women. *Stefan Zajic, Stefaan Rossenu, David Hreniuk, Filippos Kesisoglou, Jacqueline McCrea, Fang Liu, Li Sun, Rose Witter, Don Gauthier, Roy Helmy, Darrick Joss, Tong Ni, Randall Stoltz, Julie Stone, and S. Aubrey Stoch* **1450**

▣ Contextualizing Hepatocyte Functionality of Cryopreserved HepaRG Cell Cultures. *Jonathan P. Jackson, Linhou Li, Erica D. Chamberlain, Hongbing Wang, and Stephen S. Ferguson* **1463**

CYP3A Specifically Catalyzes 1 β -Hydroxylation of Deoxycholic Acid: Characterization and Enzymatic Synthesis of a Potential Novel Urinary Biomarker for CYP3A Activity. *Martin A. Hayes, Xue-Qing Li, Gunnar Grönberg, Ulf Diczfalusy, and Tommy B. Andersson* **1480**

Evaluation of Clopidogrel Conjugation Metabolism: PK Studies in Man and Mice of Clopidogrel Acyl Glucuronide. *Simona Nicoleta Savu, Luigi Silvestro, Mariana Surmeian, Lina Remis, Yuksel Rasit, Simona Rizea Savu, and Constantin Mircioiu* **1490**

Identification of Genetic Polymorphisms of *CYP2W1* in the Three Main Chinese Ethnicities: Han, Tibetan, and Uighur. *Yanwei Li, Xing Kang, Ge Yang, Penggao Dai, Chao Chen, and Huijuan Wang* **1510**

Chemical Structure and Concentration of Intratumor Catabolites Determine Efficacy of Antibody Drug Conjugates. *Donglu Zhang, Shang-Fan Yu, Yong Ma, Keyang Xu, Peter S. Dragovich, Thomas H. Pillow, Luna Liu, Geoffrey Del Rosario, Jintang He, Zhonghua Pei, Jack D. Sadowsky, Hans K. Erickson, Cornelis E. C. A. Hop, and S. Cyrus Khojasteh* . . . **1517**

▣ Functional Integrity of the Chimeric (Humanized) Mouse Liver: Enzyme Zonation, Physiologic Spaces, and Hepatic Enzymes and Transporters. *Edwin C. Y. Chow, Jason Z. Ya. Wang, Holly P. Quach, Hui Tang, David C. Evans, Albert P. Li, Jose Silva, and K. Sandy Pang* **1524**

▣ Occupancy of Nociceptin/Orphanin FQ Peptide Receptors by the Antagonist LY2940094 in Rats and Healthy Human Subjects. *Eyas Raddad, Amy Chappell, Jeffery Meyer, Alan Wilson, Charles E. Ruegg, Johannes Tauscher, Michael A. Statnick, Vanessa Barth, Xin Zhang, and Steven J. Verfaillie* **1536**

ERRATA

Correction to “Variability in Expression of CYP3A5 in Human Fetal Liver”. **1459**

Correction to “A Recombinant Humanized Anti-Cocaine Monoclonal Antibody Inhibits the Distribution of Cocaine to the Brain in Rats”. **1460**

Correction to: Cytochrome P450 and Non-Cytochrome P450 Oxidative Metabolism: Contributions to the Pharmacokinetics, Safety, and Efficacy of Xenobiotics. **1516**

▣ Supplemental material is available online at <http://dmd.aspetjournals.org>.

About the cover: Sample image of [11C]NOP-1A uptake in the same human subject at baseline and at 2.5 hours and 26.5 hours after oral dosing of LY2940094 (40 mg), respectively. See the article by Raddad et al. (dx.doi.org/10.1124/dmd.116.070359).